A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients

被引:113
作者
Dussol, Bertrand
Morange, Sophie
Loundoun, Anderson
Auquier, Pascal
Berland, Yvon
机构
[1] Hop Conception, Serv Nephrol Hemodialyse Transplantat Renale, F-13385 Marseille 5, France
[2] Hop St Marguerite, Ctr Invest Clin, Marseille, France
[3] Fac Med, Unit Epidemiol Prevent & Sante Publ, Marseille, France
关键词
contrast nephropathy; furosemide; randomized trial; renal failure; saline hydration; theophylline;
D O I
10.1093/ndt/gfl133
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Contrast nephropathy (CN) is a common cause of renal dysfunction that may be prevented by saline hydration and by drugs such as theophylline or furosemide. Whether oral saline hydration is as efficient as intravenous saline hydration is unknown. The preventive efficacy of theophylline and furosemide for CN remains controversial. The purpose of the current study was to evaluate the efficacy of oral saline hydration and of intravenous saline hydration plus theophylline or furosemide for the prevention of CN. Methods. We prospectively studied 312 patients with chronic renal failure (serum creatinine 201 +/- 81 mu mol/l, Cockcroft clearance 37 +/- 12 ml/min/1.73 m(2)), who were undergoing various radiological procedures with a non-ionic, low osmolality contrast agent. Patients were randomly assigned to four arms. In arm A, patients received 1 g/10 kg of body weight/day of sodium chloride per os for 2 days before the procedure. In arm B, patients received 0.9% saline intravenously at a rate of 15 ml/kg for 6 h before the procedure. In arm C, patients received the same saline hydration as in arm B plus 5 mg/kg theophylline per os in one dose 1 h before the procedure. In arm D, patients received the same saline hydration as in arm B plus 3 mg/kg of furosemide intravenously just after the procedure. Results. Patients were well-matched with no significant differences at baseline in any measured parameters. Acute renal failure, defined as an increase in serum creatinine of 44 mu mol/l (0.5 mg/dl), occurred in 27 out of 312 patients (8.7%). There was no significant difference between the rate of renal failure in the different arms of the study: five out of 76 (6.6%) in arm A, four out of 77 (5.2%) in arm B, six out of 80 (7.5%) in arm C and 12 out of 79 (15.2%) in arm D. No patient had fluid overload or a significant increase in blood pressure in the 2 days following the radiological procedure. The independent predictors of CN were diabetes mellitus, high baseline serum creatinine and high systolic blood pressure. Conclusions. Oral saline hydration was as efficient as intravenous saline hydration for the prevention of CN in patients with stage 3 renal diseases. Furosemide and theophylline were not protective.
引用
收藏
页码:2120 / 2126
页数:7
相关论文
共 39 条
[1]   Role of adenosine in the renal responses to contrast medium [J].
Arakawa, K ;
Suzuki, H ;
Naitoh, M ;
Matsumoto, A ;
Hayashi, K ;
Matsuda, H ;
Ichihara, A ;
Kubota, E ;
Saruta, T .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1199-1206
[2]   Prevention of radiocontrast-induced nephropathy [J].
Asif, A ;
Epstein, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (01) :12-24
[3]   Nephrotoxic effects in high-risk patients undergoing angiography. [J].
Aspelin, P ;
Aubry, P ;
Fransson, S ;
Strasser, R ;
Willenbrock, R ;
Berg, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :491-499
[4]   Preventing nephropathy induced by contrast medium [J].
Barrett, BJ ;
Parfrey, PS .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (04) :379-386
[5]   CONTRAST NEPHROPATHY IN PATIENTS WITH IMPAIRED RENAL-FUNCTION - HIGH VERSUS LOW OSMOLAR MEDIA [J].
BARRETT, BJ ;
PARFREY, PS ;
VAVASOUR, HM ;
MCDONALD, J ;
KENT, G ;
HEFFERTON, D ;
ODEA, F ;
STONE, E ;
REDDY, R ;
MCMANAMON, PJ .
KIDNEY INTERNATIONAL, 1992, 41 (05) :1274-1279
[6]  
BARRETT BJ, 1994, J AM SOC NEPHROL, V5, P125
[7]   MECHANISMS OF DISEASE - HYPOXIA OF THE RENAL MEDULLA - ITS IMPLICATIONS FOR DISEASE [J].
BREZIS, M ;
ROSEN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :647-655
[8]   High-dose furosemide for established ARF: A prospective, randomized, double-blind, placebo-controlled, multicenter trial [J].
Cantarovich, F ;
Rangoonwala, B ;
Lorenz, H ;
Verho, M ;
Esnault, VLM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (03) :402-409
[9]   HIGH DOSE FRUSEMIDE IN ESTABLISHED ACUTE RENAL-FAILURE [J].
CANTAROVICH, F ;
GALLI, C ;
BENEDETTI, L ;
CHENA, C ;
CASTRO, L ;
CORREA, C ;
PEREZLOR.J ;
FERNANDEZ, JC ;
LOCATELLI, A ;
TIZADO, J .
BMJ-BRITISH MEDICAL JOURNAL, 1973, 4 (5890) :449-450
[10]   CARDIOVASCULAR AND RENAL TOXICITY OF A NONIONIC RADIOGRAPHIC CONTRAST AGENT AFTER CARDIAC-CATHETERIZATION - A PROSPECTIVE TRIAL [J].
DAVIDSON, CJ ;
HLATKY, M ;
MORRIS, KG ;
PIEPER, K ;
SKELTON, TN ;
SCHWAB, SJ ;
BASHORE, TM .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (02) :119-124